The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis

Psoriasis poses a significant economic burden. A systematic review of psoriasis treatments cost and effectiveness has been performed extensively in the United States (US) and Europe, but such review is limited in Asia. This review aims to analyze all previous literature on the cost and effectiveness of systemic and biological treatment for moderate to severe psoriasis. Cost of illness and cost-effectiveness studies that examined the economic burden, cost, and effectiveness of psoriasis treatments (systemic and biological) in Asian region from 2010 to 2020 were published in English language. All costs were converted into 2020 US Dollar. All COIs included found that direct medical costs were greater than indirect costs. Adalimumab, ustekinumab, risankizumab, secukinumab 150 mg were cost-effective treatments and of the lowest cost per PASI-75/PASI1 and/or QALY. When comparing the different treatments, topical and systemic psoriasis treatments were observed to be the most cost-effective compared with other modalities. Given the tremendous economic effects of psoriasis on patients and hospitals, economic analysis, clinicians, and policymakers should consider cost and effectiveness evidence, as this systematic literature review was conducted to analyze previous documentation regarding the cost and effectiveness of systemics and biologics in Asian countries.

Download Full-text

Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States

Journal of Psoriasis and Psoriatic Arthritis ◽

10.1177/2475530319842174 ◽

2019 ◽

Vol 4 (3) ◽

pp. 133-142

Author(s):

Steven R. Feldman ◽

Jashin J. Wu ◽

April W. Armstrong ◽

Mark Lebwohl ◽

Abby A. Jacobson ◽

...

Keyword(s):

United States ◽

Cost Effectiveness ◽

Treatment Cost ◽

Severity Index ◽

The United States ◽

Severe Psoriasis ◽

Biologic Drugs ◽

Annual Treatment ◽

The Cost ◽

Annual Treatment Cost

Objective:To provide a contemporary comparative assessment of biologic drug costs and cost effectiveness for treating moderate-to-severe psoriasis in the United States.Methods:A literature search was conducted in PubMed on October 4, 2018 with the search terms of “psoriasis,” “biologic,” and “cost” with a filter of publication dates within the last 5 years (2014-2018). Studies included in this review were required to be conducted from a United States perspective.Results:Of the 16 studies retrieved, the costs associated with use of biologic drugs for the treatment of moderate-to-severe psoriasis were relatively high, with some drugs exhibiting sustained lower costs than others. Some comparative findings on the cost-effectiveness of biologic drugs based on the annual treatment cost per Psoriasis Area and Severity Index (PASI) 75 responder concluded that the annual treatment cost was lowest for brodalumab 210 mg at US$48 782; the cost was highest for ustekinumab 45/90 mg (US$87 243), followed by adalimumab 40 mg (US$82 655), ixekizumab 160 mg (US$77 957), and secukinumab 300 mg (US$75 671). The annual treatment cost per PASI 100 responder was also lowest for brodalumab at US$87 585. This pattern remained consistent in other cost studies, with brodalumab being the treatment with the lowest treatment costs when compared to other biologic drugs.Conclusion:Brodalumab was consistently observed to be the least costly treatment option among biologic drugs used to treat moderate-to-severe psoriasis in the United States, which is largely the result of its low-drug cost and high-PASI response rate.

Download Full-text

Faculty of 1000 evaluation for Analysis of the Cost Effectiveness of Home-Based Phototherapy With Narrow-Band UV-B Radiation Compared With Biological Drugs For the Treatment of Moderate to Severe Psoriasis.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.715597801.791053052 ◽

2012 ◽

Author(s):

Robert Dawe

Keyword(s):

Cost Effectiveness ◽

Narrow Band ◽

Severe Psoriasis ◽

Biological Drugs ◽

Home Based ◽

The Cost

Download Full-text

Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia

International Journal of Health Policy and Management ◽

10.15171/ijhpm.2019.17 ◽

2019 ◽

Vol 8 (7) ◽

pp. 394-402

Author(s):

Nor Azmaniza Azizam ◽

Aniza Ismail ◽

Saperi Sulong ◽

Norazirah Md Nor

Keyword(s):

Cost Effectiveness ◽

Treatment Options ◽

Life Quality ◽

Severity Index ◽

Severe Psoriasis ◽

Public Hospitals ◽

Treatment Modalities ◽

Psoriasis Area Severity Index ◽

Cost Effective Treatment ◽

The Cost

Background: There is limited evidence detailing the cost-effectiveness of psoriasis treatments in the Asian region. Therefore, this study is aimed to evaluate the cost-effectiveness of 3 psoriasis treatments tailored for moderate to severe psoriasis, namely topical and phototherapy (TP), topical and systemic (TS), and topical and biologic (TB) regimens, respectively. Methods: This has been achieved by the participation of a prospective cohort involving a total of 90 moderate to severe psoriasis patients, which has been conducted at 5 public hospitals in Malaysia. The main outcome measures have been evaluated via cost and effectiveness psoriasis area severity index (PASI)-75 and/or body surface area (BSA) <5 and/or dermatology life quality index (DLQI) ≤5), estimated from the societal perspective over a 6-months duration. All costs are based on 2015’s recorded Malaysian Ringgit (RM) currency. Results: Consequently, TS has been found to be the most cost-effective treatment with the lowest cost/PASI-75/and/or BSA <5 and/or DLQI ≤5, valued at RM9034.56 (US$2582.55). This is followed by TP, which is valued at RM28 080.71 (US$8026.93) and TB, valued at RM54 287.02 (US$15 518.06). Furthermore, one-way sensitivity analysis has highlighted the cost of medication as the most sensitive parameter. Conclusion: Thus, the input from this study is helpful for policy-makers in determining the first line treatment for moderate to severe psoriasis with consideration of the costs and its effectiveness in Malaysia. This will consequently allow hospitals to justify and provide the essential resources for further research and development, as well as the adoption of better treatment options.

Download Full-text